27 November 2024 : Clinical Research
Evaluation of Cardiometabolic Risk in Patients with Non-Functioning Adrenal Adenomas Using the Systematic Coronary Risk Evaluation 2 (SCORE2) and the Systematic Coronary Risk Evaluation 2-Older Persons (SCORE2-OP) Algorithms
Marzena Jabczyk
1ABDEF, Justyna Nowak 2ABCDE*, Sylwia Mielcarska 3CD, Bartosz Hudzik 2AC, Kinga Wołkowska-Pokrywa 3B, Elżbieta Świętochowska 3BC, Barbara Zubelewicz-Szkodzińska 14ABEFG
DOI: 10.12659/MSM.945899
Med Sci Monit 2024; 30:e945899
Table 3 Comparison of glucose metabolism parameters between the SCORE2 and SCORE2-OP groups.
| Parameter | CVD risk based on SCORE-OP/SCORE-OP2 | P value | ||
|---|---|---|---|---|
| Low and moderate risk (N=16) | High risk (N=28) | Very high risk (N=62) | ||
| Fasting glucose [mmol/L] | 5.35 (5.08–5.61) | 5.78 (5.39–6.03) | 5.83 (5.22–6.28) | ,a |
| Glucose after 120 min [mmol/L] (glucose tolerance test) | 7.20 (6.33–7.92) | 7.19 (5.87–8.75) | 6.39 (5.61–7.92) | 0.5449 |
| Glucose after 60 min [mmol/L] (glucose tolerance test) | 11.92 (9.25–12.28) | 9.85 (9.61–12.21) | 9.42 (7.83–11.22) | 0.2054 |
| Fasting insulin [pmol/L] | 12.30 (7.20–13.40) | 6.60 (4.60–35.80) | 6.15 (4.30–9.65) | 0.08 |
| Insulin after 60 min [pmol/L] (glucose tolerance test) | 139.40 (38.50–170.90) | 53.85 (35.80–90.40) | 55.05 (40.70–76.60) | 0.1225 |
| HbA1C [%] | 5.59±0.33 | 5.74±0.28 | 5.92±0.67 | 0.29 |
| HOMA-IR index | 1.07 (1.01–3.40) | 1.61 (1.07–2.46) | 2.28 (1.4–3.04) | 0.2735 |
| HbA1C – glycated hemoglobin; HOMA-IR – homeostatic model assessment for insulin resistance. Kruskall-Wallis test with the post hoc multiple comparison test. a Kruskall-Wallis test: significant difference for: low risk vs high risk; b Kruskall-Wallis test: significant difference for: low risk vs moderate risk. | ||||